Charles Ndiaye's questions to Travere Therapeutics Inc (TVTX) leadership • Q3 2024
Question
Charles Ndiaye from Stifel Financial Corp. asked about the company's current expectations for the Loss of Exclusivity (LOE) timeline for sparsentan in IgAN and how those expectations might change.
Answer
President and CEO Dr. Eric Dube stated that the company's current base planning assumption for LOE is into 2033. He also noted that the full approval in IgAN granted an additional term of orphan drug exclusivity through September 2031, providing another layer of protection.